Preclinical study links cardiometabolic stress to HFpEF and bioenergetic impairment in aged mice

A preclinical study reported that cardiometabolic stress induces heart failure with preserved ejection fraction (HFpEF) alongside impaired bioenergetics and disrupted proteostasis in aged female mice.

Researchers reported that inducing cardiometabolic stress in aged female mice triggers heart failure with preserved ejection fraction (HFpEF).

The study observed that this induced state is characterised by compromised cardiac tissue bioenergetics and disrupted proteostasis pathways.

HFpEF represents a major therapeutic gap in cardiovascular medicine, particularly affecting older female populations, with few targeted interventions currently available.

By establishing a direct link between systemic cardiometabolic stress and localised bioenergetic and proteostatic decline, the study helps map specific cellular hallmarks of aging to clinical organ dysfunction.

The identification of bioenergetic failure as a driver of HFpEF reinforces the therapeutic rationale for platforms targeting mitochondrial health and cellular energy pathways.

Companies developing NAD+ precursors and biosynthesis modulators may see increased interest in evaluating their assets within the context of age-related cardiometabolic and cardiovascular preservation.

Preclinical or investigator-led studies evaluating whether clinical-stage NAD+ precursors or proteostasis regulators can rescue cardiac bioenergetic deficits and improve diastolic function in aged HFpEF models.